Researchers at Northwestern Medicine have identified immune system markers that may help predict who responds to BCG bladder cancer therapy and who does not, according to findings published in the Journal of Clinical Investigation. The discovery could lead to personalized treatment strategies for patients with non-muscle invasive bladder cancer, a common form of the disease.
BCG (Bacillus Calmette-Guérin) therapy is a standard immunotherapy for bladder cancer, but it is effective in only about 50% of patients. Currently, doctors have no reliable way to determine which patients will benefit, often leading to delayed alternative treatments for non-responders. The new biomarkers, which include specific immune cell populations and genetic signatures, could change that.
The study analyzed tumor samples from bladder cancer patients before and during BCG treatment. Using advanced molecular profiling, the team identified distinct immune profiles that correlated with treatment success. Patients with a higher presence of certain T-cell subtypes and specific cytokine patterns were more likely to respond favorably. Conversely, those with a predominance of immunosuppressive cells tended to have poor outcomes.
These findings align with ongoing efforts by companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) to refine immunotherapy approaches. Calidi is developing novel stem cell-based platforms to deliver therapeutic agents directly to tumors, potentially enhancing the immune response. While the Northwestern study focuses on predictive biomarkers, Calidi's work aims to improve treatment efficacy, highlighting the multifaceted progress in cancer immunotherapy.
The implications of this research are significant. If validated in larger clinical trials, these biomarkers could become a routine part of bladder cancer management, allowing doctors to tailor therapy from the outset. Patients unlikely to benefit from BCG could be directed to alternative treatments such as chemotherapy, targeted therapy, or newer immunotherapies, avoiding unnecessary side effects and delays. This personalized approach could improve survival rates and quality of life.
Bladder cancer is the sixth most common cancer in the United States, with an estimated 82,000 new cases annually. Non-muscle invasive bladder cancer accounts for about 70% of diagnoses, and BCG has been the gold standard for decades. However, its variable efficacy and the lack of predictive tools have been persistent challenges.
The Northwestern team plans to further validate their biomarkers in prospective studies and explore whether similar immune signatures apply to other cancers treated with immunotherapy. The research was supported by the National Institutes of Health and other funding agencies.
While the study represents a step forward, experts caution that more work is needed before clinical implementation. The biomarkers must be standardized and tested in diverse patient populations. Nonetheless, the findings offer a promising path toward precision medicine in bladder cancer.
